Breaking Down Yixintang Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

Dive into a data-driven snapshot of Yixintang Pharmaceutical Group (002727.SZ): through the first three quarters of 2025 the company reported operating revenue of CNY 13 billion (down 4.33% YoY) with net profit attributable to shareholders at CNY 269 million (down 8.17%) and core net profit after non-recurring items at CNY 253 million (down 26.27%); profitability shows a 32.4% gross margin (Q3 2024) but net margin slid to 0.3% as selling expenses rose to 27.2%, ROE and ROA sit at 1.09% and 1.29% while ROIC is 2.01%; balance sheet and liquidity paint a conservative leverage profile with total debt of CNY 2.03 billion against CNY 3.42 billion cash and equivalents (net cash CNY 1.39 billion), debt-to-equity 0.38, interest coverage 9.28 and operating cash flow CNY 1.72 billion covering capex of CNY 254.8 million; valuation metrics range from a trailing P/E of 86.87 to a forward P/E of 13.96, EV/EBITDA 2.84 and EV/FCF 4.58, while risks include a CNY 386 million impairment provision, rising selling costs and a quick ratio of 0.75-read on for the full breakdown of these figures, their implications and the growth initiatives targeting store expansion, digitalization and product-line optimization.

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Revenue Analysis

Yixintang Pharmaceutical Group's top-line and profitability trends in 2025 show modest contraction in revenue with larger relative declines in core net profit after adjusting for non-recurring items, signaling margin pressure and operational challenges.

• Operating revenue for the first three quarters of 2025: CNY 13.00 billion (YoY -4.33%).
• Net profit attributable to shareholders (first three quarters 2025): CNY 269 million (YoY -8.17%).
• Net profit attributable to shareholders after deducting non-recurring gains/losses (first three quarters 2025): CNY 253 million (YoY -26.27%).
• Operating revenue for the first half of 2025: CNY 8.914 billion (YoY -4.20%).
• Net profit attributable to parent company (first half 2025): CNY 250 million (YoY -11.44%).
• Net profit excluding non-recurring gains/losses (first half 2025): CNY 243 million (YoY -18.41%).

• Revenue trajectory: a small but consistent decline (~4.2-4.33% YoY) indicates demand or pricing pressure across core product lines in 2025.
• Profitability gap: net profit fell more sharply than revenue, and adjusted (core) profit contracted even more - core operations show margin compression or higher operating costs.
• Timing and comparability: the deeper decline in adjusted profits over the first three quarters (-26.27%) versus the first half (-18.41%) suggests incremental headwinds in Q3 2025.
• Investor focus areas: cost control, gross margin trends by product, and the composition/recurrence of non-operating items affecting adjusted profit.

For broader context on shareholder composition and market interest in the stock, see: Exploring Yixintang Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Profitability Metrics

• Gross margin stability (32.4%) indicates product-level pricing/COGS management is broadly intact.
• Sharp drop in net margin to 0.3% reflects non-production cost pressure-chiefly selling expenses rising to 27.2%.
• High selling expense ratio suggests increased marketing, distribution, or channel costs that are not yet converting to higher margins.
• ROE (1.09%), ROA (1.29%), and ROIC (2.01%) all point to low return generation - investors should weigh these against industry peers and capital structure.

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Debt vs. Equity Structure

• Debt-to-Equity Ratio: 0.38 - indicates low reliance on debt relative to shareholder equity.
• Debt-to-EBITDA: 1.07 - suggests EBITDA covers total debt roughly 1.07 times.
• Debt-to-Free Cash Flow: 1.73 - free cash flow can cover total debt about 1.73 times.
• Interest Coverage Ratio: 9.28 - EBIT or EBITDA covers interest expense 9.28 times, signaling strong ability to service interest.

• Liquidity position: cash and equivalents (CNY 3.42bn) exceed total debt (CNY 2.03bn), providing immediate financial flexibility and potential for opportunistic investments or deleveraging.
• Capital structure: EV (CNY 7.47bn) versus market cap (CNY 7.70bn) shows enterprise valuation closely aligned with equity market value, implying limited market-implied leverage adjustments.
• Coverage and solvency: strong interest coverage (9.28) and modest debt-to-EBITDA (1.07) reduce refinancing and default risk under moderate earnings volatility.

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Yixintang Pharmaceutical Group Co., Ltd. highlight a generally healthy short-term position and strong ability to service debt, while inventory dependence reduces immediate quick-liquidity. Relevant figures are summarized below.

• Current ratio: 1.31 - sufficient short-term assets to cover short-term liabilities.
• Quick ratio: 0.75 - below 1.0, suggesting reliance on inventory to meet near-term obligations.
• Cash and equivalents: CNY 3.42 billion - sizable cash buffer.
• Total debt: CNY 2.03 billion - modest leverage relative to cash.
• Net cash position: CNY 1.39 billion - cash minus total debt.
• Operating cash flow: CNY 1.72 billion - strong cash generation from operations.
• Capital expenditures: CNY 254.8 million - comfortably covered by operating cash flow.
• Interest coverage ratio: 9.28 - robust ability to meet interest expenses.

For broader context on the company's background and business model, see Yixintang Pharmaceutical Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Valuation Analysis

Yixintang Pharmaceutical Group's valuation profile presents a mix of growth expectations and conservative asset-based valuation metrics. Key multiples reflect investor optimism about near-term earnings growth while signaling modest pricing relative to sales and book value.

• Trailing vs. forward P/E gap: 86.87 vs. 13.96 - implies earnings turnaround is priced in or that trailing earnings were depressed by one-off items.
• Low P/S (0.44) suggests revenue base is valued conservatively; potential upside if margins recover.
• P/B ~1.03 indicates limited goodwill premium; balance sheet not deeply overvalued.
• EV/EBITDA 2.84 and EV/FCF 4.58 point to attractive enterprise-level pricing relative to cash generation.

Contextual considerations for investors:

• High trailing P/E warrants review of recent earnings drivers and non-recurring items.
• Forward P/E requires validation against management guidance and consensus forecasts.
• Compare EV/EBITDA and EV/FCF to peers in Chinese pharmaceutical manufacturing and specialty drug segments to assess relative cheapness.
• Monitor cash flow conversion and balance sheet health to confirm the low EV/FCF is sustainable.

Further corporate context and historical background can be found here: Yixintang Pharmaceutical Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Risk Factors

• Asset impairment: management recorded a CNY 386 million provision for impairment on a long-term equity investment, directly reducing operating profit and net income in the reporting period.
• Profitability pressure: net profit margin has declined year-over-year from approximately 8.5% to 4.2%, indicating tighter margins and reduced earnings power.
• Rising selling costs: the selling expense ratio increased from about 6.1% to 8.7% of revenue, raising the company's fixed/variable cost burden and pressuring operating margins.
• Liquidity concerns: the quick ratio stands below 1 at ~0.78, signaling limited near-term liquid resources to meet short-term obligations without relying on inventory liquidation.
• Competitive and policy risks: heightened industry competition and ongoing healthcare policy changes (centralized procurement, reimbursement reforms) create revenue volatility and margin compression.

• Market competition - generics and branded rivals can force price concessions, reducing gross margins.
• Policy shifts - centralized procurement and reimbursement adjustments can rapidly alter demand and pricing for core products.
• One-off impairments - the CNY 386m charge demonstrates downside to equity investments and the importance of balance-sheet quality.
• Operational cost trends - rising selling expense ratio may persist unless sales efficiency or pricing power improves.
• Working capital and liquidity - quick ratio below 1 warrants monitoring of cash conversion cycles, receivables, and short-term financing reliance.

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Growth Opportunities

• Store network expansion: target of 11,516 stores by end-2024 (a 15.1% increase vs. current network of ~10,007 stores).
• Digital transformation: establishment of a wholly-owned digital subsidiary aiming for a comprehensive digital model by early 2025.
• Operational efficiency measures: rent negotiations, tighter cost control, and category optimization to lift margins and cash conversion.
• Product and portfolio strategy: strengthening Great Southern TCM varieties and fostering key product lines to boost brand influence.
• Channel strategy: accelerate terminal sales network penetration and prioritize e-commerce to capture omnichannel demand.

• Investor considerations: store roll-out speed, execution of the digital model by early 2025, and realized cost savings will be primary drivers of near-term margin improvement and top-line scalability.
• Risks tied to expansion: store unit economics, lease renegotiation success, and competitive pressure in e-commerce.